Bucladesine

Heart failure is a chronic cardiovascular disease with high incidence globally. Traditional positive inotropic drugs are prone to cause adverse reactions such as arrhythmia and increased myocardial oxygen consumption, and there has been a long-term gap in safe clinical medication. Bucladesine is an anti-heart failure drug of the cyclic adenosine monophosphate class. It activates protein kinase A to promote calcium ion influx and enhance myocardial contractility, while dilating peripheral blood vessels to reduce cardiac load, and also inhibiting platelet aggregation to improve microcirculation. It is mainly used for the treatment of acute heart failure and perioperative cardiac insufficiency in cardiac surgery, and can also be used for symptomatic support in patients with ischemic heart disease combined with cardiac insufficiency, especially for the patient group intolerant to traditional digitalis drugs.

At present, the global market size of bucladesine is relatively small, and there is no publicly verifiable industry statistical data. The clinical application scenarios of this variety are mostly concentrated in in-hospital first aid and perioperative management, with strong and relatively stable rigid demand. The domestic market has long been dominated by the supply of Japanese original research products, with few generic drug layout enterprises, and the overall competitive pattern is relatively loose. With the improvement of the diagnosis and treatment rate of cardiovascular diseases in China and the gradual improvement of perioperative cardiac function management specifications, the market demand is expected to maintain a steady growth trend.

The original research enterprise of bucladesine is Daiichi Sankyo Co., Ltd. of Japan, with the original research trade name "Colander", and the core compound patent has expired. The dosage form approved for the original research product is injection, with a specification of 30mg per vial. This product is not included in the Chinese *Catalogue of Reference Preparations for Chemical Drugs*, and it is also not included in the FDA Reference Preparations Catalogue. As of June 2025, there is no valid registration information of bucladesine active pharmaceutical ingredient (API) in the database of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, and no preparation product of this variety has been approved for marketing in China. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for bucladesine API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use requirements in different stages such as API R&D, quality research, and registration declaration.